☆ 4.6 Review

Fluorine in Medicinal Chemistry: In Perspective to COVID-19

ACS OMEGA (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Chemistry, Multidisciplinary

Biological Utility of Fluorinated Compounds: from Materials Design to Molecular Imaging, Therapeutics and Environmental Remediation

Cheng Zhang et al.

Summary: This review discusses the applications of fluorinated molecules in bioengineering and nanotechnology, with a focus on controlling fluorine-fluorine interactions and understanding their impact on biological behavior. The controlled introduction of fluorine and its interactions can provide advantages in imaging, therapeutics, and environmental applications.

CHEMICAL REVIEWS (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses

Andreas Luttens et al.

Summary: Developing drug inhibitors targeting SARS-CoV-2 is crucial for saving lives and preparing for future outbreaks. Two virtual screening strategies were explored, resulting in the identification of compounds with inhibitory effects, including one compound with promising antiviral activity.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)

添加到收藏夹

Review Multidisciplinary Sciences

4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication

Julien Sourimant et al.

Summary: This study describes a drug called 4'-fluorouridine (4'-FlU), which has broad-spectrum antiviral effects and potential for the treatment of respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and related RNA virus infections. In vitro and in vivo experiments showed that 4'-FlU inhibited RSV, SARS-CoV-2, and related RNA viruses with high efficacy, making it a promising candidate for broad-spectrum therapeutics against respiratory viruses.

SCIENCE (2022)

添加到收藏夹

News Item Critical Care Medicine

The role of antiviral treatment in the COVID-19 pandemic

Talha Khan Burki

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay

Wenyue Cao et al.

Summary: The researchers developed an effective method to analyze the cellular potency of main protease (MPro) inhibitors for their toxicity and antiviral effect against SARS-CoV-2. Some antiviral agents showed weak cellular MPro inhibition potency, suggesting their involvement in interfering with other key steps in the virus life cycle. One of the inhibitors, MPI8, exhibited the highest cellular and antiviral potency, indicating the need for further research.

ACS CENTRAL SCIENCE (2022)

添加到收藏夹

Editorial Material Infectious Diseases

The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era

Huahao Fan et al.

LANCET MICROBE (2022)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CLProtease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh et al.

Summary: S-217622 is the first oral noncovalent, nonpeptidic SARS-CoV-2 3CL protease inhibitor clinical candidate, which could be a potential oral agent for treating COVID-19.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Letter Medicine, General & Internal

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Infectious Diseases

Role of favipiravir in the treatment of COVID-19

Shashank Joshi et al.

Summary: Favipiravir has shown promising results in clinical studies worldwide, demonstrating potential efficacy against COVID-19, and is being included in treatment protocols by multiple countries.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

Sylwester Drozdzal et al.

Summary: The COVID-19 pandemic poses a significant threat to global health with various therapeutic agents initially proclaimed to be effective, but later disproved. The Pfizer agent PAXLOVIDTM has shown promising results in reducing hospitalization time and death rates. Further development of additional treatments is needed due to the insufficiency of current recommended therapeutic options.

DRUG RESISTANCE UPDATES (2021)

添加到收藏夹

Article Microbiology

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

Steven S. Good et al.

Summary: AT-527, an oral antiviral drug, has potent activity against various coronaviruses, including SARS-CoV-2. In vitro experiments have shown that AT-511 has high efficacy in inhibiting the replication of SARS-CoV-2, with minimal cytotoxicity. Studies suggest that AT-527 may be an effective treatment option for COVID-19.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

添加到收藏夹

Article Microbiology

Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro

Kaho Shionoya et al.

Summary: Mefloquine, an anti-malarial drug, demonstrated higher anti-SARS-CoV-2 activity than Hydroxychloroquine, inhibiting viral entry to target cells and showing synergistic antiviral activity when combined with other drugs. Mathematical modeling predicted that standard dosage of Mefloquine could reduce viral load and shorten the time until virus elimination in patients.

FRONTIERS IN MICROBIOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Drug repurposing screens identify chemical entities for the development of COVID-19 interventions

Malina A. Bakowski et al.

Summary: The study presents a screening pipeline to discover SARS-CoV-2 inhibitors, identifying 49 compounds in HeLa-ACE2 and 41 in Calu-3 capable of selectively inhibiting virus replication. Antivirals nelfinavir and parent of prodrug MK-4482 show promising activity in vitro and in animal models.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

Flavio A. Cadegiani et al.

Summary: Proxalutamide significantly accelerated viral clearance on Day 7 in mild to moderate COVID-19 patients compared to placebo. Additionally, the time to clinical remission was significantly reduced in patients treated with Proxalutamide compared to placebo.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Tuning of the Aggregation Behavior of Fluorinated Polymeric Nanoparticles for Improved Therapeutic Efficacy

Cheng Zhang et al.

ACS NANO (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

添加到收藏夹

Review Chemistry, Multidisciplinary

Contribution of Organofluorine Compounds to Pharmaceuticals

Munenori Inoue et al.

ACS OMEGA (2020)

添加到收藏夹

Article Chemistry, Organic

Favipiravir - a Modern Antiviral Drug: Synthesis and Modifications

Yulia A. Titova et al.

CHEMISTRY OF HETEROCYCLIC COMPOUNDS (2020)

添加到收藏夹

Letter Public, Environmental & Occupational Health

Dexamethasone: A boon for critically ill COVID-19 patients?

Shailesh Kumar Patel et al.

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)

添加到收藏夹

Article Infectious Diseases

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

Anahita Sadeghi et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir

Steffen Jockusch et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Integrating Fluorinated Polymer and Manganese-Layered Double Hydroxide Nanoparticles as pH-activated 19F MRI Agents for Specific and Sensitive Detection of Breast Cancer

Cheng Zhang et al.

SMALL (2019)

添加到收藏夹

Article Polymer Science

PFPE-Based Polymeric 19F MRI Agents: A New Class of Contrast Agents with Outstanding Sensitivity

Cheng Zhang et al.

MACROMOLECULES (2017)

添加到收藏夹

Article Oncology

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Review Chemistry, Multidisciplinary

Fluorine in medicinal chemistry

Sophie Purser et al.

CHEMICAL SOCIETY REVIEWS (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.